LifeVantage reported revenue of $48.9 million for the quarter ended December 31, 2025, down 27.8% year-over-year but up 2.9% sequentially. Americas revenue fell 32.6% as MindBody GLP-1 System sales cycled its October 2024 launch, while Asia/Pacific & Europe revenue declined 2.1% (3.7% on a constant currency basis). Gross profit decreased to $36.2 million (74.0% of revenue) from $54.6 million (80.5%), reflecting a $2.4 million inventory obsolescence charge on GLP-1 inventory and higher shipping costs; non-GAAP gross profit was $38.6 million (78.8%). Commissions and incentives expense improved to 40.7% of revenue from 48.0%, and SG&A rose to 32.3% of revenue from 27.5%, driven by lower sales volume. Operating income was $0.5 million versus $3.4 million a year ago; adjusted non-GAAP operating income was $2.6 million. Net income was $0.3 million, or $0.02 per diluted share, compared to $2.6 million, or $0.19 per share; adjusted net income was $1.9 million, or $0.15 per share, versus $3.0 million, or $0.22. Adjusted EBITDA totaled $3.9 million, down from $6.5 million. Cash from operations was $0.5 million for the first half of fiscal 2026, cash and equivalents stood at $10.2 million at December 31, 2025, and the company has no debt. During the period, LifeVantage repurchased 44,000 shares for $0.6 million and announced a new $60 million buyback through December 2027, and declared a cash dividend of $0.045 per share payable March 16, 2026.

Management forecasts full-year fiscal 2026 revenue of $185 million to $200 million, adjusted EBITDA of $15 million to $19 million, and adjusted EPS of $0.60 to $0.80, assuming a tax rate of 22% to 24%. Guidance excludes potential non-operating or one-time charges. The company plans to stabilize the GLP-1 business, expand LoveBiome® offerings into high-growth categories over the next quarters, and enter new international markets this summer and beyond. With a strong balance sheet and ongoing capital return programs, LifeVantage aims to drive long-term shareholder value through product innovation and global expansion.

After nine years as President and Chief Executive Officer, Steve Fife will retire in April 2026. He will remain in his role through the transition to ensure continuity. Raymond Greer, Board Chairman, noted that comprehensive succession planning has been underway and an extensive executive search is in progress, with a new CEO announcement expected in the coming months. Fife credited the leadership team with evolving the business model and strengthening market position, expressing confidence in the company's future trajectory and the Board's ability to guide the next growth chapter.